MA27009A1 - Derives de pyrazole pour le traitement d'une infection par le vih - Google Patents

Derives de pyrazole pour le traitement d'une infection par le vih

Info

Publication number
MA27009A1
MA27009A1 MA27336A MA27336A MA27009A1 MA 27009 A1 MA27009 A1 MA 27009A1 MA 27336 A MA27336 A MA 27336A MA 27336 A MA27336 A MA 27336A MA 27009 A1 MA27009 A1 MA 27009A1
Authority
MA
Morocco
Prior art keywords
treatment
derivatives
present
pyrazole derivatives
hiv infection
Prior art date
Application number
MA27336A
Other languages
English (en)
Inventor
Lyn Howard Jones
David Anthony Price
Paul Anthony Stupple
Charles Eric Mowbray
Matthew Duncan Selby
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0108999A external-priority patent/GB0108999D0/en
Priority claimed from GB0127426A external-priority patent/GB0127426D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27009A1 publication Critical patent/MA27009A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 10 Avril 2001 0108999.4 GB 15 Novembre 2001 0127426.5 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de pyrazole pour le traitement d'une infection par le VIH La présente invention concerne des dérivés de pyrazole de formule (I), ou leurs sels, produits de solvatation ou dérivés pharmaceutiquement acceptables, formule dans laquelle R1 à R4 répondent aux définitions dans la description, et des procédés pour leur préparation, les intermédiaires utilisés dans leur préparation, des compositions les contenant et les utilisations de ces dérivés. Les composés de la présente invention se lient à l'enzyme consistant en transcriptase inverse et sont des modulateurs, notamment des inhibiteurs, de cette enzyme. Pour cette raison, les composés de la présente invention sont utiles dans le traitement de diverses affections, comprenant celles dans lesquelles l'inhibition de la transcriptase inverse est impliquée. Des affections intéressantes comprennent celles provoquées par le virus d'immunodéficience humaine (VIH) et par des rétrovirus génétiquement apparentés, par exemple le syndrome d'immunodéficience acquise (SIDA),
MA27336A 2001-04-10 2003-10-06 Derives de pyrazole pour le traitement d'une infection par le vih MA27009A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108999A GB0108999D0 (en) 2001-04-10 2001-04-10 Pyrazole derivatives
GB0127426A GB0127426D0 (en) 2001-11-15 2001-11-15 Pyrazole derivatives

Publications (1)

Publication Number Publication Date
MA27009A1 true MA27009A1 (fr) 2004-12-20

Family

ID=26245955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27336A MA27009A1 (fr) 2001-04-10 2003-10-06 Derives de pyrazole pour le traitement d'une infection par le vih

Country Status (42)

Country Link
US (4) US7109228B2 (fr)
EP (2) EP1377556B1 (fr)
JP (1) JP3806090B2 (fr)
KR (1) KR100569324B1 (fr)
CN (1) CN100408564C (fr)
AR (2) AR037319A1 (fr)
AT (2) ATE358669T1 (fr)
AU (1) AU2002242926B2 (fr)
BG (1) BG66349B1 (fr)
BR (1) BRPI0208811B8 (fr)
CA (1) CA2443449C (fr)
CR (1) CR7069A (fr)
CY (2) CY1107626T1 (fr)
CZ (1) CZ305099B6 (fr)
DE (1) DE60219292T2 (fr)
DK (2) DK1377556T3 (fr)
DO (1) DOP2002000378A (fr)
EA (1) EA007184B1 (fr)
EE (1) EE05400B1 (fr)
ES (2) ES2385659T3 (fr)
GE (1) GEP20053619B (fr)
HR (1) HRP20030783B1 (fr)
HU (1) HU229025B1 (fr)
IL (2) IL157875A0 (fr)
IS (1) IS2734B (fr)
MA (1) MA27009A1 (fr)
ME (1) ME00558A (fr)
MX (1) MXPA03009380A (fr)
MY (1) MY146669A (fr)
NO (1) NO326518B1 (fr)
NZ (1) NZ529403A (fr)
OA (1) OA12501A (fr)
PA (1) PA8543601A1 (fr)
PE (1) PE20021056A1 (fr)
PL (3) PL216985B1 (fr)
PT (2) PT1762567E (fr)
RS (1) RS51166B (fr)
SI (2) SI1377556T1 (fr)
SK (1) SK287858B6 (fr)
TW (1) TWI333488B (fr)
UY (1) UY27248A1 (fr)
WO (1) WO2002085860A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05400B1 (et) * 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
WO2003057673A1 (fr) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation Composes derives de 1h-pyrozolyle, pouvant etre utilises dans les maladies associees au recepteur 5-ht2c
JP4228587B2 (ja) 2002-05-22 2009-02-25 昭和電工株式会社 アミノメチル基含有ベンズアミド化合物の製造方法
US20040132793A1 (en) * 2002-09-16 2004-07-08 Pfizer Inc. Pyrazole derivatives
GB0221477D0 (en) * 2002-09-16 2002-10-23 Pfizer Ltd Chemical compounds
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
WO2005013888A2 (fr) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Composes, compositions et procedes
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
CA2554696C (fr) 2004-02-13 2009-06-30 Warner-Lambert Company Llc Modulateurs du recepteur d'androgene
EP1737813A1 (fr) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Modulateurs d'androgenes
WO2005102990A1 (fr) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Modulateurs des androgenes
AR048650A1 (es) * 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
CA2570047C (fr) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxybenzonitriles utilises comme modulateurs d'androgenes
EP1874732A1 (fr) 2005-04-20 2008-01-09 Pfizer Limited Derives de pyrazole tenant lieu d'antagonistes du recepteur de la progesterone
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EA014693B1 (ru) * 2005-11-08 2010-12-30 Пфайзер Лимитед Терапевтически активные соединения
ES2566481T3 (es) 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
EP2057125B1 (fr) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Inhibiteurs de la transcriptase inverse non nucléoside
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy
US9280685B2 (en) * 2006-12-08 2016-03-08 Johnnie R. Jackson System and method for portable medical records
WO2008135824A1 (fr) * 2007-05-02 2008-11-13 Pfizer Limited Composés d'oxyalkylpyrazole utiles en thérapie
MX2009013865A (es) 2007-06-22 2010-01-27 Hoffmann La Roche Urea y derivados carbamato como inhibidores no nucleosidicos de la transcriptasa inversa.
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CA2701594C (fr) 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Antagonistes de canaux calciques de type t a base de phenyle amide heterocyclique
EP2225239B1 (fr) 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Composés hétérocycliques antiviraux
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
EP2558007A4 (fr) * 2010-04-13 2017-11-29 Sentreheart, Inc. Procédés et dispositifs pour l'accès et l'implantation de dispositifs dans un coeur
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
WO2013050873A1 (fr) 2011-10-07 2013-04-11 Phivco Uk Limited Procédé de préparation de lersivirine
WO2013050884A1 (fr) 2011-10-07 2013-04-11 Phivco Uk Limited Procédé pour la préparation de lersivirine
WO2013057593A1 (fr) 2011-10-07 2013-04-25 Phivco Uk Limited Procédé de préparation de dérivés de lersivirine
EP2716632A1 (fr) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
US9695127B2 (en) 2012-11-08 2017-07-04 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating HIV and methods for using the compounds
US10026064B2 (en) 2013-09-13 2018-07-17 Microsoft Technology Licensing, Llc Automatically recommending updates based on stored lifecycle information
WO2015060348A1 (fr) * 2013-10-23 2015-04-30 大日本住友製薬株式会社 Dérivé de pyrazole fusionné
EP3140289A1 (fr) * 2014-05-06 2017-03-15 E. I. du Pont de Nemours and Company Pyrazoles fongicides
EP3760208B1 (fr) 2014-06-25 2024-05-29 The General Hospital Corporation Ciblage de hsatii (human satellite ii)
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
JOP20180092A1 (ar) * 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
KR102114389B1 (ko) * 2018-05-02 2020-05-25 이화여자대학교 산학협력단 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020056564A1 (fr) 2018-09-17 2020-03-26 南通纺织丝绸产业技术研究院 Procédé de préparation d'un composé 1,3-dicarbonyle à base d'un système composite hydrure métallique/palladium
JP2022504982A (ja) * 2018-10-18 2022-01-13 南京聖和薬業股▲ふん▼有限公司 ＴＧＦ－βＲ１阻害剤としての化合物及びその応用
CN113527304B (zh) * 2020-04-17 2025-08-12 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的制备方法
CN113527306B (zh) * 2020-04-17 2025-06-24 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的晶型
KR20250023466A (ko) 2022-06-15 2025-02-18 닛산 가가쿠 가부시키가이샤 피라졸 화합물, 그 제조 중간체 및 유해 생물 방제제
EP4692065A1 (fr) 2023-03-31 2026-02-11 Nissan Chemical Corporation Composé pyrazole et agent de lutte contre les organismes nuisibles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303200A (en) * 1963-11-05 1967-02-07 American Home Prod Pyrazole-1-ethanol derivatives
US3963742A (en) * 1974-07-12 1976-06-15 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents
US4009277A (en) * 1975-01-17 1977-02-22 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents
US4041046A (en) 1975-06-06 1977-08-09 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazole compounds
US4000301A (en) 1975-11-14 1976-12-28 American Cyanamid Company Fungicidal use of 4-alkoxypyrazoles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH0565237A (ja) 1991-09-10 1993-03-19 Mitsubishi Heavy Ind Ltd メタノールを媒体としたエネルギ供給方法
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
WO1994022830A1 (fr) 1993-03-31 1994-10-13 Smithkline Beecham Corporation Composes chimiques
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
DE69408950T2 (de) 1993-12-14 1998-10-15 Mitsubishi Chem Corp N-Pyrazolylcarbamatderivate und Fungizide für Landwirtschaft und Gartenbau, die diese als aktive Bestandteile erhalten, Produktion und Zwischenprodukte
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
DE69532245T2 (de) * 1994-09-26 2004-09-16 Shionogi & Co., Ltd. Imidazolderivat
TW343232B (en) * 1994-10-13 1998-10-21 Chisso Corp Difluorooxymethane derivative and liquid crystal composition
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
MXPA02010993A (es) * 2000-05-12 2003-03-10 Genzyme Corp Reguladores de transmision de la tnf-alfa.
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
EE05400B1 (et) * 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks

Also Published As

Publication number Publication date
JP2004531535A (ja) 2004-10-14
BR0208811A (pt) 2004-03-09
BRPI0208811B8 (pt) 2021-05-25
DK1377556T3 (da) 2007-07-16
WO2002085860A1 (fr) 2002-10-31
EA007184B1 (ru) 2006-08-25
KR100569324B1 (ko) 2006-04-07
CZ305099B6 (cs) 2015-05-06
IL157875A0 (en) 2004-03-28
HK1063781A1 (zh) 2005-01-14
ATE358669T1 (de) 2007-04-15
EP1762567A1 (fr) 2007-03-14
SI1762567T1 (sl) 2012-08-31
PL396946A1 (pl) 2012-01-02
US20060020012A1 (en) 2006-01-26
IS6939A (is) 2003-09-04
PL217224B1 (pl) 2014-06-30
AR076259A2 (es) 2011-06-01
NZ529403A (en) 2005-06-24
US8063044B2 (en) 2011-11-22
HUP0303735A3 (en) 2004-07-28
CY1107626T1 (el) 2013-04-18
YU77503A (sh) 2006-05-25
JP3806090B2 (ja) 2006-08-09
AR037319A1 (es) 2004-11-03
RS51166B (sr) 2010-10-31
KR20040007496A (ko) 2004-01-24
CN100408564C (zh) 2008-08-06
CN1514828A (zh) 2004-07-21
NO20034523L (no) 2003-12-09
PE20021056A1 (es) 2002-12-03
MY146669A (en) 2012-09-14
CA2443449A1 (fr) 2002-10-31
HRP20030783A2 (en) 2005-08-31
UY27248A1 (es) 2002-11-29
ME00558A (en) 2011-12-20
AU2002242926B2 (en) 2007-10-11
PL398536A1 (pl) 2012-06-04
PL216985B1 (pl) 2014-06-30
US20090215712A1 (en) 2009-08-27
CZ20032676A3 (cs) 2004-11-10
SK287858B6 (sk) 2012-01-04
EP1377556B1 (fr) 2007-04-04
OA12501A (en) 2006-05-26
CA2443449C (fr) 2008-11-04
EE05400B1 (et) 2011-04-15
US20030100554A1 (en) 2003-05-29
DK1762567T3 (da) 2012-06-25
PL365026A1 (en) 2004-12-27
NO20034523D0 (no) 2003-10-09
EA200300943A1 (ru) 2004-08-26
BG66349B1 (bg) 2013-08-30
BRPI0208811B1 (pt) 2018-03-13
EP1762567B1 (fr) 2012-05-02
US20120029192A1 (en) 2012-02-02
CR7069A (es) 2007-12-17
TWI333488B (en) 2010-11-21
ES2385659T3 (es) 2012-07-27
MXPA03009380A (es) 2004-04-21
PT1762567E (pt) 2012-07-16
NO326518B1 (no) 2008-12-22
US7109228B2 (en) 2006-09-19
PA8543601A1 (es) 2002-10-31
GEP20053619B (en) 2005-09-26
HU229025B1 (en) 2013-07-29
BG108244A (bg) 2005-04-30
EP1377556A1 (fr) 2004-01-07
ATE556059T1 (de) 2012-05-15
PT1377556E (pt) 2007-06-06
HUP0303735A2 (hu) 2004-03-01
DOP2002000378A (es) 2002-10-15
US7435728B2 (en) 2008-10-14
DE60219292D1 (de) 2007-05-16
ES2283532T3 (es) 2007-11-01
EE200300497A (et) 2004-02-16
IL157875A (en) 2010-05-17
HRP20030783B1 (hr) 2011-11-30
SI1377556T1 (sl) 2007-08-31
CY1113515T1 (el) 2016-06-22
PL217629B1 (pl) 2014-08-29
DE60219292T2 (de) 2008-04-10
SK12442003A3 (sk) 2004-12-01
IS2734B (is) 2011-04-15

Similar Documents

Publication Publication Date Title
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MY146669A (en) Pyrazole derivatives for treating hiv
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
DE60318874D1 (en) Pyrazolderivate
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH
ATE386741T1 (de) Pyrazolamide zur behandlung von hiv-infektionen
MA30924B1 (fr) Analogues de pyrazoles
MA29855B1 (fr) Inhibiteurs de l'enzyme integrase du vih
TNSN03088A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
TNSN05072A1 (fr) Derives de 4-(3,5-dicyanophenoxy) pyrazole destines a etre utilises comme modulateurs de transcriptase dans le traitement d'affections provoquees par le vih
MA26705A1 (fr) Derives d'hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB0223234D0 (en) Chemical compounds
AP1846A (en) Pyrazole Derivatives.
MA28302A1 (fr) Derives de sulfonamides pour le traitement de maladies
TNSN08154A1 (fr) Inhibiteurs de l'enzyme integrase du vih
TNSN03129A1 (fr) Inhibiteurs de protease du vih, compositions les contenant , leurs utilisation pharmaceutiques, et matieres pour leur synthese .